Busting Up Big Medicine: A bipartisan plan to curb costs and restore competition

A bipartisan Break Up Big Medicine Act would prohibit insurers, PBMs and drug wholesalers from owning healthcare providers, aiming to break up the largest six Big Medicine players to lower drug costs and restore competition. The piece argues consolidation helps drive up prices, cites FTC findings and state-level reforms as progress, and notes rising public support for such antitrust–leaning healthcare reforms.